tevanj, I put up a link to some previous posts. Case # is 11-704-LPS
tevanj, the patent suit was filed back in Aug 2011 in Del. dst court. If you follow this thread back, you should see some of the initial dockets. I can give you the case # if you have PACER, but you can also just query Actavis or Avanir to get it.
During the first quarter of 2013, issued 650,000 common shares to an institutional investor in consideration for aggregate proceeds of approximately $3.4 million.
By my figures, that equates to about $5.23, so the institution is a bit underwater on that deal. That said, I'm also a bit underwater on my buys here.
ps, boobird is a nick I use for happy occasions.
From yesterday's 10Q (pg 27):
On August 10, 2012, our Board of Directors authorized the repurchase of up to $100 million of our outstanding common stock through August 1, 2013. The previous authorization was for up to $25 million and covered the period through December 31, 2012. During the three months ended March 31, 2013, we repurchased 235,000 shares of our common stock for an aggregate purchase price of $1.7 million. We have purchased an aggregate to date of $13.6 million or 1,338,055 shares. All shares of treasury stock were retired at March 31, 2013.
By my calc, SPPI paid around $7.23/share for those 235,000 shares.
They placed some shares with inst. investors - I believe Christine said $19M - this is under their agreement with Cowen.
Lorcaserin is a new chemical entity and is not currently available or marketed in any country.
According to publicly available information reviewed by DEA, lorcaserin is anticipated to enjoy
patent protection for at least a decade before generic equivalents may be manufactured and
I'm a relative newbie - is this correct?
Earnings for Q1 last year were announced May 8. Previous year was May 10. I believe AMRN is an accelerated filer, which means they have to file 10Q by the 10th.
Accompanied by a decline in the closing pps over the last 5 days. Today's volume of 400,000 with almost an hour of trading to go guarantees that we'll get another bump in volume, but will the closing share price continue to decline?
May 1 367,300 $2.69
Apr 30 303,000 $2.80
Apr 29 200,500 $2.80
Apr 26 142,900 $2.85
Apr 25 131,200 $2.89
Clip from that news report:
Officials said the overall jump in reserves was chiefly due to production now thought to be accessible in the Three Forks Formation, in the southern edge of North Dakota, which had not been tallied in the last study.
"Three Forks is up and coming," said Brenda Pierce, coordinator for the Energy Resources Program at the U.S. Geological Survey (USGS).
Rapid development in the Three Forks region means that recoverable reserves are higher than the USGS estimate, energy experts said.
overall non-GAAP gross margin came in at 61%,
OpEx minus restructuring, stock-based comp & amort. of intangible assets gave a non-GAAP OpEx of $44.7M, so it looks as if they did even better than what I saw at first glance.
Hopefully they'll underpromise and overdeliver on Q2 & 2013.
2013 First Quarter and Full Year Outlook
The Company’s outlook is based on current indications for its business, which may change during the current quarter. Gross margin, operating expenses and EPS are presented on a non-GAAP basis. A reconciliation of the non-GAAP to GAAP outlook and a statement on the use of non-GAAP financial measures are included at the end of this press release.
First Quarter 2013
Total Revenue $60 to $62 million // They reported $63.3M
SBC Total Revenue $26 to $27 million // They reported $30M
SBC Product Revenue $21 to $22 million // They reported $23.5M
Gross Margin 61% to 62% // They reported 59.7% overall, 63.2% GM on product
Operating Expenses $45 to $46 million // They reported $51.2M - not sure if restructuring included.
Basic EPS $(0.03) // $( 0.02) non-GAAP
Cash & Investments $280 million // Looks like $276M
This may give the street confidence in their predictions for next quarter & the year.
My guess is sometime between May 5th & 10th. Previous Q1 earnings releases:
2008 - May 13
2009 - May 18
2010 - May 10
2011 - May 4
2012 - Apr 26
SEC requires filing of 10Q by May 10, so if they meet that deadline, we should see a report by the 10th or before.
The proxy statement shows him with 2,445,725 shares of SONS, with this note:
Includes 815,104 shares subject to outstanding options that are exercisable as of May 15, 2013 and 1,172,356 shares of restricted stock and performance-based restricted stock subject to vesting.